ACC vs AMBUJACEM
Side-by-side comparison of ACC Ltd. and Ambuja Cements Ltd.. Descriptive only — not investment advice.
ACC Ltd.
Cement
Quality Score: 39/100
Ambuja Cements Ltd.
Cement
Quality Score: 33/100
At a glance
| Metric | ACC | AMBUJACEM |
|---|---|---|
| Quality Score | 39/100 | 33/100 |
| P/E (trailing) | 13.2 | 23.8 |
| Forward P/E | 13.6 | 29.2 |
| ROE | — | — |
| Profit margin | +7.6% | +11.1% |
| Debt-to-equity | 2.08 | 1.21 |
| Dividend yield | +0.55% | +0.46% |
| 1Y price return | -25.4% | -26.6% |
| From 52w high | -31.3% | -28.6% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.68 | 1.97 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
ACC trades at ₹1,357.60, down 25.4% over the past year and 31.28% below its 52-week high, with 5-year earnings down 60.6% against a 3.8% revenue decline over the same window. Quality score stands at 21/100 with no tracked year showing ROE above 15%, and Q1 FY27 profit fell to ₹147 crore. Mean analyst rating is 2.68 across 24 analysts (1-5 scale, lower = more constructive).
Ambuja Cements trades at Rs 430.85, just above its 50-DMA (Rs 428.58) but 28.65% below its 52-week high and down 26.6% over the trailing 12 months. Trailing PE is 23.77x within a Cement peer set spanning ACC's 13.2x to Shree Cement's 56.5x, while 5-year earnings are down 27.5% against a smaller 7.7% revenue decline. Free cash flow was positive in only 1 of the tracked years, and the mean analyst rating stands at 1.97 across 38 analysts (1-5 scale, lower = more constructive).
Pros
- ✓PE of 13.21 (forward 13.64) is the lowest among the 6 tracked cement peers, versus GRASIM (45.5), ULTRACEMCO (40.6), SHREECEM (56.5), DALBHARAT (36.8), and AMBUJACEM (23.8).
- ✓Debt-to-equity is low in absolute terms at roughly 0.02x (raw metric 2.085 on a percent-scaled basis).
- ✓3-month price change is roughly flat at -0.92%, with the stock sitting just above its 50-DMA (₹1,354.78 vs price ₹1,357.60) and RSI neutral at 47.83.
- ✓Q1 FY27 revenue of ₹5,808 crore and EBITDA of ₹457 crore were reported alongside the quarter, per July 24, 2026 coverage.
- ✓PE of 23.77x is below 4 of the 5 other tracked cement peers, with only ACC (13.2x) lower, placing the multiple in the cheaper half of the sector range.
- ✓Absolute balance-sheet leverage is low: debt-to-equity of approximately 0.01x once the percent-scaled raw metric (1.205) is adjusted.
- ✓RSI reads neutral at 48.36 with price holding just above its 50-DMA (Rs 428.58) rather than showing an oversold extreme.
- ✓Mean analyst rating of 1.97 across 38 analysts (1-5 scale, lower = more constructive) sits toward the constructive end of the tracked coverage universe.
Cons
- ✗5-year earnings growth of -60.6% against revenue growth of -3.8%; free cash flow was positive in only 1 of the tracked years, with a persistence consistency score of 34/100.
- ✗ROE has not exceeded 15% in any tracked year (roeYearsAbove15 = 0), and quality score of 21/100 ranks 5th of 6 tracked cement peers.
- ✗Stock is down 25.4% over the trailing 12 months and trades 31.28% below its 52-week high, remaining below the 200-DMA (₹1,540.62) despite sitting just above the 50-DMA.
- ✗News flow skews negative (4 of 8 sampled items negative vs 2 positive), including disclosure of a SEBI administrative warning to a former Company Secretary and Q1 FY27 profit falling to ₹147 crore.
- ✗Free cash flow was positive in only 1 of the tracked years, indicating a persistent gap between cash generation and capital needs despite low balance-sheet leverage.
- ✗5-year earnings are down 27.5% against a smaller 7.7% revenue decline, and ROE has not exceeded 15% in any tracked year (consistency score of 0).
- ✗Quality score of 19 ranks last (6th of 6) among tracked cement peers (ACC 21, GRASIM 25, DALBHARAT 30, SHREECEM 39, ULTRACEMCO 43).
- ✗Stock is down 26.6% over the trailing 12 months and 28.65% below its 52-week high, trading below its 200-DMA (Rs 481.84).
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.